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 INTRODUCTION
Contagious bovine pleuropneumonia (CBPP) is an important
disease of cattle in Africa caused by Mycoplasma mycoides subsp.
mycoides biotype small colony (MmmSC) and characterized by
extensive lesions of pleurisy and pneumonia (13). Among
infectious diseases that threaten African cattle, its importance is
only second to rinderpest (RP) and, as more and more countries
declare being free of RP, CBPP is likely to become the major
priority for Veterinary Services in that continent.
In Africa, the control measures for CBPP are mainly based on
vaccination with an empirically attenuated strain (15). Eradication
has recently been achieved by stamping out policies in Botswana
(11) but its cost has been tremendous and it is unlikely that other
countries in Africa can afford it. Cattle owners often use antibiotic
treatments in the field but officially these treatments are
discouraged or forbidden because of the fear that they can promote
the emergence of chronic carriers, resistant mycoplasma strains
and antibiotic residues in human food. Therefore, control policies
by vaccination seemed to be the obvious choice. It had been
applied extensively in the past in many countries between the 60s
and the 80s (2, 8), leading to the control or the eradication of the
disease in many African countries after several years of repeated
vaccination campaigns.
However, in the 90s CBPP has reemerged as a major disease. It
reappeared in countries where it had been eradicated such as
Rwanda, Kenya, Tanzania, Mauritania, and the number of
outbreaks increased in countries where it was previously under
control (10). This reemergence could well be the consequence of
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Summary
Contagious bovine pleuropneumonia (CBPP) is an important disease of cattle
causing serious losses to the livestock industry in Africa. It is controlled primarily
through vaccination. However, recent observations in the field indicate that the
vaccine in current use failed to protect cattle in the face of outbreaks causing
concern to the veterinary authorities of affected countries. A field trial was
carried out to determine the causes for vaccine failure. T1/44 and T1sr vaccine
strains of Mycoplasma mycoides subsp. mycoides (small colony) were used to
vaccinate a group of 40 cattle per strain. Half of these cattle were challenged at
three months and the other half at 15 months following vaccination, respectively.
Half of the cattle used in the second trial were revaccinated one year after the
primary vaccination. A dose of 107 mycoplasmas per milliliter was used in
primary as well as secondary vaccinations. In the first challenge (at three months
post the primary vaccination), the efficacy was 68.2 and 59% for T1sr and T1/44
vaccines, respectively. In the second challenge, the efficacy was 80.5 and 95.5%
for T1sr and T1/44 vaccines, respectively, in cattle vaccinated twice, while in
cattle vaccinated once and challenged at 15 months post primary vaccination
the efficacy was 28.7 and 78.2% for T1sr and T1/44, respectively. These results
confirm what had been obtained in previous trials but they also bring valuable
new information. They show that a single vaccination, whatever the strain used,
at the minimum required dose does not give satisfactory protection and that full
protection can only be achieved by revaccination. Consequences for future
vaccine trials and research needs are discussed.
1. National Veterinary Research Centre, Kenya Agricultural Research Institute,
P.O. Box 32, Kikuyu, Kenya
2. CIRAD-EMVT, TA 30/G, Campus international de Baillarguet, 34398
Montpellier Cedex 5, France
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many factors such as the stop of the rinderpest vaccination
campaigns that permitted the concomitant vaccination against
CBPP in West Africa or the lack of preparedness in countries that
had not been confronted to the disease for many years. More
alarmingly some experts suggested that this reemergence could
well be the consequence of a lack of protection afforded by the
vaccinal strain T1sr as compared to the strains used in the past,
former stocks of T1sr or T1/44.
This is why it was decided to conduct a comprehensive vaccination
trial under the framework of EU/DG1 development funding and the
supervision of OAU/IBAR2, Nairobi. These trials had a precise
objective: evaluate the protection afforded by a single injection at
the minimum dose required by international standards, i.e., 107
viable mycoplasmas per dose (14) for T1sr and T1/44 strains by a
contact challenge performed three months after the vaccination.
These trials were to be performed in three different African
locations, Cameroon, Kenya and Namibia, in order to take into
account the genetic variability of the MmmSC strains that could be
correlated to a modification of the potency of the vaccine (1, 17). In
addition, a second protocol was designed in Kenya to assess the
protection afforded one year after vaccination. This protocol was
subsequently modified after initial results showed a very low
protection with a challenge three months after the vaccination. The
modification included the revaccination of some animals in order to
assess the subsequent protection afforded.
 MATERIALS AND METHODS
Schematic Trial Protocol
- Purchase of susceptible animals;
- Initial pathogenicity testing of three MmmSC strains;
- Vaccination of 40 cattle with T1sr vaccine and 40 with T1/44 at
107 per dose.
Three months later:
- Intubation of 40 animals to serve as donors. They were put into
contact with 40 unvaccinated control animals. Twenty T1sr
vaccinated and 20 T1/44 vaccinated animals;
- Follow-up of these animals for two months after the initial
clinical signs in the control group;
- Termination of the experiment by necropsy of all animals.
Twelve months later: Revaccination of 10 animals with T1sr and
10 animals with T1/44 (at the minimum 107 dose).
Fifteen months later (three months after revaccination): Intubation
of 40 animals to serve as donors. They were put into contact with
40 unvaccinated animals. Ten animals vaccinated once with T1sr,
10 animals vaccinated once with T1/44, 10 animals vaccinated
twice with T1sr and 10 animals vaccinated twice with T1/44.
Animals
Cattle were purchased from Kakamega District of Western
Province, Kenya, historically known to be free of CBPP. Before
purchase, 100 cattle from various homes in the district were
randomly sampled for serum and found free of antibodies against
MmmSC by the complement fixation test (CFT), the OIE3 official
serological test (14), and by cELISA (7), the new alternative test
accepted by OIE. Following this, 255 cattle from the district were
sampled and purchased for use in the experiment. The animals
were transported to the experimental site at KARI4 Muguga at the
beginning of the rainy season. On arrival at the experimental site,
the cattle were vaccinated against foot and mouth disease, lumpy
skin disease, black quarter, anthrax and Rift Valley fever. 
Initial Pathogenicity Trial
Fifteen animals were randomly divided into three groups of five
animals. Each group was kept in a different house separated by a
distance of 40 m. Each group was inoculated by a different strain,
group one with the Gladysdale strain which had been traditionally
used in former trials, group two with an MmmSC strain isolated in
Rwanda in 1994, and group three with a local Kenyan isolate. The
Gladysdale strain, originally isolated from Australia, had been kept
at NVRC5-KARI since 1960 and the field isolate from Rwanda
was isolated and characterized by CIRAD-EMVT6 for the official
confirmation of CBPP in that country. For the first two groups, the
inoculation was performed intratracheally with 60 ml of an
MmmSC pure culture followed by 30 ml of 1% suspension of low
melting agar. Group three was inoculated intratracheally with 
30 ml of a lung suspension obtained from a natural case of CBPP
followed by the inoculation of 100 ml of normal saline. All
animals were observed for eight weeks after which period the
survivors were slaughtered.
Vaccination
Forty animals were vaccinated subcutaneously in the middle of the
neck with T1sr at the dose of 107 viable mycoplasmas per animal;
40 animals were similarly vaccinated with T1/44. The vaccine
batches were supplied by CIRAD-EMVT after they had
successfully passed quality control at PANVAC7, Debre Zeit,
Ethiopia. After vaccination, the local reaction was thoroughly
checked every day and the diameter of the swelling site evaluated
by palpation. One year later, after the initial challenge had been
completed, ten animals were randomly selected from each
vaccinated group and subsequently revaccinated with the same
vaccine batches, T1sr or T1/44, under the same conditions.
Intubation Protocol and Challenge by Contact
Each animal was sedated with 2 ml of Chanazine 2% (2%
xylocaine) injected intramuscularly. Fifteen minutes later the
animal was made to lie on its right side and a one meter long, 
10 mm wide in diameter, tube was inserted into the trachea. A
narrower tube, 1.5 m long and 2 mm wide, was inserted into the
wider tube and pushed into the trachea. The narrower tube was
used to inject the infective preparation. In the first trial performed
three months after the initial vaccination, the inoculum consisted
of 60 ml of a pure culture of the Kenyan isolate followed by 30 ml
of a lung suspension in normal saline. In the second challenge
performed 15 months after the initial vaccination, the lung
suspension was replaced by 30 ml of 1% agar suspension.
The group of intubated animals was observed for one week and the
contact was performed when the first signs of disease appeared in
that group, as measured by hyperthermia. Forty naive animals, 
20 animals vaccinated with T1sr and 20 animals vaccinated by
T1/44, were introduced into the premises occupied by the
intubated animals and kept in close contact thereafter.
1. European Union/Directorate General
2. Organization of African Unity/Inter-African Bureau for Animal Resources 
3. Office international des épizooties
4. Kenya Agricultural Research Institute
5. National Veterinary Research Centre
6. Centre de coopération internationale en recherche agronomique pour le
développement, département d’élevage et de médecine vétérinaire
7. Pan African Vaccine Laboratory 
Retour au menu
Etudes expérimentales sur l’efficacité des vaccins T1sr et T1/44 
315
R
ev
ue
 É
le
v.
 M
éd
. v
ét
. P
ay
s 
tr
op
., 
20
00
, 5
3 
(4
) :
 3
13
-3
18
Follow-up of Animals
Rectal temperatures were taken daily. Serum samples were
harvested before the challenge and every other week after
vaccination. In the second experiment, animals were bled monthly
after the vaccination, then every other week after the beginning of
the challenge. During each challenge, the animals that survived the
disease were slaughtered two months after the initial clinical signs
had been observed in the control group, namely fever for three
consecutive days. Clinical signs and lesions were noted and
transcribed into a pathological score as described by Hudson and
Turner (5) in order to calculate a protection rate. Briefly, this
pathological score is calculated as follows:
- The presence of only encapsulated resolving or fibrous lesions or
the presence of pleural adhesions only are rated 1;
- If other types of lesions are present, namely consolidated, acute,
necrotic or sequestrated, these lesions are rated 2;
- This initial score is then multiplied by a factor depending on the
size of the lesions: 1 (the lesion size is under 5 cm), 2 (it is over 5
and under 20 cm) and 3 (it is over 20 cm).
Hence the maximum pathology score is 2 x 3 = 6.
Serum samples were analyzed by CFT, competition ELISA, but
also by indirect ELISA as described previously (19).
 RESULTS
Postvaccinal Reaction
Some swelling occurred at the injection site between days 6 and
29. None of them occurred in the T1sr group (swelling less than 
2 cm in diameter). Conversely, there were 15 animals in the T1/44
group that exhibited a swelling of more than 2 cm in diameter.
Five of them had noticeable swellings (more than 6 cm in
diameter) and one developed a severe invading necrosis at the
shoulder, together with fever and was subsequently slaughtered. A
mycoplasma strain was isolated from the skin lesion and identified
as a T1 vaccinal strain by a specific polymerase chain reaction (9).
Initial Pathogenicity Trial
All five cattle infected with the Kenyan inoculum (made of lung
suspension) showed clinical signs of CBPP and lesions from which
MmmSC was isolated again. Comparatively, the other inoculum
failed to reproduce CBPP, therefore it was decided to use the
Kenyan isolates for the subsequent challenges.
Intubation and Transmission Success
This success can be evaluated by analyzing the temperature, the
serological results and the lesions found after death or slaughter.
Temperature 
The temperature of healthy animals was always below 39°C as
animals with CBPP had intermittent fever with temperatures
ranging from 39.5 to 40.5°C. The number of animals exhibiting
fever in each group at a defined day was used to monitor the
efficacy of disease uptake after intubation or disease transmission
to the control groups. In the first trial intubation was quite
successful but the rate of transmission to the control group was
rather low. In the second experiment the opposite situation
prevailed, intubation transmitted CBPP in only five animals but
these five animals contaminated the control group very efficiently.
Based on the data on animals exhibiting fever in the different
groups, the incubation period lasted 57 days in the first experiment
and 40 days in the second.
Serology
During the first trial the five animals that exhibited fever in the
intubated group also exhibited a seroconversion as measured by
indirect ELISA except for one animal that died rapidly, 20 days
after inoculation. Conversely four animals exhibited a
seroconversion while not exhibiting any fever after intubation.
None of these animals displayed any lesion nor any fever
afterwards either, an indication that they were probably protected
by the initial intubation. Out of the 31 animals left, 14 (45%) did
not exhibit any fever afterwards as compared to 11 out of 40
(27%) in the control group. This difference seems to indicate that
some of the intubated animals did not contract CBPP nor exhibit
any seroconversion were nevertheless protected. Protection may
not be strictly correlated with seroconversion as measured by this
indirect ELISA.
In the control groups, seroconversion took place after the initial
occurrence of fever but it must be noted that temperature was
recorded daily and blood samples were taken only every 15 days.
The precise date when an animal was seroconverting was
impossible to obtain. However, in three cases seroconversion was
seen prior to the observation of fever. As seroconversion
necessarily follows multiplication of MmmSCs, these results
showed that fever may not be triggered by multiplication of
mycoplasmas but simply reflects the intensity of lesions. This
hypothesis may be substantiated by the analysis of the lesions
observed after necropsy.
Necropsy and Pathology Index
To investigate if there was any correlation between fever and
intensity of lesions, it was decided to cumulate for each animal the
number of days with fever during the whole trial and to compare
these data with the lesions observed in the end, as measured by the
Hudson and Turner index. Animals were grouped according to
their pathology index and, in each group, the distribution of the
number of days with fever analyzed. It is clear that there is an
overall correlation between the intensity of lesions and the number
of days with fever (Table I). The mean day numbers with fever in
each group is strictly correlated with the pathology index.
However, this correlation is not always true at the individual level
as some animals exhibiting a high pathology score (4 or 6)
apparently did not exhibit many days with fever.
Evaluation of Protection
The protection rate was calculated according to Hudson and
Turner by comparing pathological scores in the vaccinated and in
the control groups. A single injection gave apparently a similar
protection, regardless of the type of vaccine, 59% for T1/44 and
68.2% for T1sr (Table II). Similarly, the protection afforded by
two vaccinations at a one-year interval was very good, regardless
of the type of vaccine, 80.4% for T1sr and 95% for T1/44 (Table
III). A marked difference was noted when the challenge was
performed 15 months after a single vaccination. The protection
afforded by the T1sr dose dropped at 28%, whereas the protection
afforded by the T1/44 was maintained at a relatively high level,
78,2% (Table III).
It is noteworthy that the intensity of the challenge was quite mild
during the first trial, with a mean pathology score of 2.2 in the
control group, but very high in the second trial, with a mean
pathology score of 4.6. This last result indicates that the protection
rates observed in the second trial are very robust as it is unlikely that
animals in the field will be confronted to such a harsh challenge.
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 DISCUSSION AND CONCLUSION
There was an obvious difference between the two trials in Kenya
in terms of transmission success. In spite of an apparent success of
intubation in the first trial, the transmission to the contact animals
did not occur as rapidly as in the second trial. This was quite
surprising as apparently the intubation was less successful in the
second trial with only five animals being infected primarily. This
difference cannot be explained by trivial factors as the same type
of animals and the same challenge strain was used. The only
explanation should be found in additional factors that differed
between the two trials. The body condition could be one of them,
this body condition was not very good in the first trial as the
animals had been inadvertently infested by liverfluke during
grazing before the experiment and fed with lower quality fodder
during the experiment. If this were the case, it would mean that a
good body condition would be a predisposing factor for CBPP.
This could be explained by the fact that during a CBPP outbreak,
as lesions are triggered by an overwhelming immune response,
only the animals capable of developing such a response are prone
to develop lesions. An additional factor can be found in the
immunomodulation effect of some parasitic infestation such as
liverfluke. This factor has already been mentioned for
trypanosomes (6). All these factors may certainly also play a role
in the ability of the vaccine to induce a good protection, something
which is often overlooked in the field and may explain some
apparent vaccination failures.
The classical Hudson and Turner score was used here to measure
the protection rate as it has frequently been the case in the past (3),
ensuring valid comparisons with former trials. It must be noted
that the present trial was slightly different from former ones as all
animals were slaughtered rapidly at the end of the experiment due
to time constraints. In former trials, animals were slaughtered after
a defined period of time following seroconversion. This slight
difference is unlikely to modify dramatically the final results
because of the rapid transmission of the disease. The Hudson and
Turner scoring system may not be completely satisfactory, the
authors themselves had mentioned that “the procedure for
calculating scores is arbitrary, and may well be susceptible to some
improvement” (5). The “total score” includes parameters such as
fever and pathology scores that are correlated, an indication that a
simplification of the scoring system could be achieved. More
importantly, means are calculated on distributions of results that
are obviously not Gaussian leading to statistical irrelevancies. In
the future it may be advisable to use comparisons with other tests
such as Chi2 and to give more weight to animals that die or suffer
from important lesions.
The constant problem encountered with CBPP experimental trials
is finance. Due to the absence of a validated in vitro or laboratory
animal model, all experiments have to be performed on cattle. The
use of mice as laboratory models (16) has to be questioned as
virulence factors of MmmSC and protection in cattle certainly
depend on specificities of the bovine immune response. The
relative difficulty to reproduce the disease by intubation
necessitates the use of a large group of intubated animals. In
addition, the somewhat unpredictable rate of transmission success
also calls for large control groups and treated animals so that
statistically meaningful results may be obtained. This is the reason
why experimental trials have to focus on specific objectives. The
relative high cost of these trials have to be put in perspective with
the probable high cost of the disease itself, but also with the
unacceptable high cost of vaccination programs if they are
performed with inadequate vaccines.
The protection afforded by a single vaccination in Kenya was quite
low 60%. A similar experiment in Cameroon reached a similar
conclusion with an even lower protection rate, 30% (18, 19). The
difference may be explained by the harsher trial in Cameroon but
the conclusion is nevertheless the same. It was expected that the
maximum protection rate would be obtained three months after
vaccination, therefore protection was not satisfactory.
Retrospectively, it explains why an emergency vaccination alone
was not able to stop the progress of CBPP when it invaded
Botswana. The present results show clearly that the choice of
vaccinal strains was not the reason for failure as both vaccinal
Num. of days Hudson and Turner pathology score
with fever 6 4 2 0
< 0 1 4 3 22
0 to 5 1 11 2 3
5 to 10 5 8 1 0
10 to 20 11 6 0 0
> 20 1 0 0 0
Mean 12 6.1 2.5 0.12
Table I
Correlation between the pathology index 
and the number of days with fever 
in the control group of the second trial
Number Mean Standard Protection
of cattle pathology deviation rate
score
Control 40 22 23
T1sr 20 7 15 682
T1/44 20 9 18 59
Table II
Summary of the protection rates in cattle vaccinated
once with the minimum recommended dose (107) 
of T1sr and T1/44 and challenged three months later
by contact with intubated animals
Number Pathology Standard Protection
of cattle score deviation rate
Control 41 46 14
T1sr once 11 33 24 28.7
T1/44 once 8 1 19 78.2
T1sr twice 10 9 14 80.4
T1/44 twice 10 2 6 95.5
Table III
Summary of the protection rate in cattle vaccinated
once with T1sr or T1/44 and challenged 15 months
later and cattle vaccinated twice at one-year interval
and challenged three months after the second injection
Retour au menu
Etudes expérimentales sur l’efficacité des vaccins T1sr et T1/44 
317
R
ev
ue
 É
le
v.
 M
éd
. v
ét
. P
ay
s 
tr
op
., 
20
00
, 5
3 
(4
) :
 3
13
-3
18
strains, T1sr and T1/44, gave similar protection rates at the
minimum required dose. 
The second experiment at KARI established interesting additional
data. First, it showed that there was a significant difference
between T1/44 and T1sr in terms of duration of protection, T1/44
still induced a protection 15 months after vaccination whereas T1sr
did not. In addition, the T1/44 protection rate apparently increased.
This may be an indication that the time needed for the
establishment of protection might be longer than three months.
However this good result must be balanced by the fact that T1/44
also induced a significant number of postvaccinal reactions, one of
them leading to the death of the animal. Second, it also showed
that a revaccination dramatically increased the protection rate to a
satisfactory level, 80 to 95%, regardless of the vaccinal strain. It
must also be noted that revaccination with T1/44 did not induce
any postvaccinal reaction.
These results fully reestablish the potency of the two vaccinal
strains T1sr and T1/44 at the minimum required dose when
animals are confronted to local pathogenic strains, the original
objective of the studies. A single vaccination induced a limited
protection and satisfactory protection could be achieved only by
revaccination. These results are quite similar to what was known
30 years ago (13), and they stress that only repeated vaccination
campaigns can achieve an acceptable protection rate in cattle
populations. They clearly specify what can be expected from the
minimum required dosage as very few, if not just one, previous
works had investigated this question (4). Future research should
focus on specific important points that will rapidly allow a better
definition of vaccination strategies. Two of them can already be
identified: first, establish if there is a dose response for an initial
vaccination and, second, specify the conditions for revaccination
timing in order to obtain the longest lasting protection. The dose
response trial is important as its conclusion may modify the
existing recommendations for minimal dosages in the vaccines. If
there is really a dose response, emergency vaccinations could be
performed with increased dosages in order to achieve a more rapid
and efficient protection. In addition, the current standards apply to
vaccines at the production site and do not take into account the
very probable loss of titer that will frequently occur in the field, a
reason why some authors advocate higher minimum standards
(12). In the present situation revaccinations seem to be a
prerequisite for the establishment of a satisfactory immunity.
However, the timing of these revaccinations and the duration of
immunity have not been clearly established yet.
Owing to budget constraints that are always increasing, it is quite
unlikely that many African countries will be able to perform
massive repeated vaccination campaigns. It is therefore clear that a
cost-benefit analysis of the different control strategies will have to
be done, taking into account the real prevalence and incidence of
CBPP in each case. This naturally calls for a preliminary
evaluation of the prevalence of CBPP with the help of
epidemiological and statistical tools that will permit minimizing
the cost. To avoid expensive trials and errors in the field,
modelization of CBPP transmission may be the cheapest means to
validate each strategy. In any case CBPP vaccines that would be
both innocuous and more effective are utterly needed.
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Résumé
Wesonga H.O., Thiaucourt F. Etudes expérimentales sur l’effi-
cacité des souches vaccinales T1sr et T1/44 de Mycoplasma
mycoides spp. mycoides (petite colonie) contre un isolat cau-
sant la péripneumonie contagieuse bovine au Kenya - Effet
d’une infection de rappel
La péripneumonie contagieuse bovine est une maladie provo-
quant de lourdes pertes dans les élevages bovins d’Afrique.
Son contrôle passe habituellement par la vaccination. Des
observations récentes ont cependant montré que les cam-
pagnes de vaccination sur le terrain actuelles ne sont pas suf-
fisantes lors de l’apparition de nouveaux foyers, situation pré-
occupante pour les responsables vétérinaires des pays
concernés. Un essai vaccinal a été réalisé sur le terrain afin de
déterminer les causes de ces échecs vaccinaux. Les souches
vaccinales T1sr et T1/44 de Mycoplasma mycoides spp.
mycoides (petite colonie) ont été utilisées pour vacciner des
groupes de 40 bovins par souche. L’épreuve virulente a été
réalisée respectivement chez la moitié des animaux trois mois
après la vaccination et chez l’autre moitié 15 mois après
celle-ci. La moitié des animaux utilisés lors de la deuxième
épreuve ont reçu un rappel un an après la primovaccination.
Les vaccinations ainsi que les rappels ont été effectués à des
doses de 107 mycoplasmes par millilitre. Au cours de la pre-
mière épreuve virulente (à trois mois après la vaccination ini-
tiale), les protections mesurées ont été de 68,2 p. 100 pour la
souche T1sr et de 59 p. 100 pour la souche T1/44. Lors de la
deuxième épreuve, les protections mesurées chez les animaux
ayant reçu une dose de rappel ont été de 80,5 p. 100 pour
T1sr et de 95,5 p. 100 pour T1/44. Pour ceux n’ayant reçu
qu’une seule dose vaccinale 15 mois auparavant, la protec-
tion mesurée a été de 28,7 p. 100 pour T1sr et de 78,2 p. 100
pour T1/44. Ces résultats confirment ceux qui avaient été
observés lors d’essais antérieurs mais ils apportent également
des éléments d’information nouveaux et importants. Il est en
particulier confirmé qu’une primovaccination avec une dose
minimale ne confère pas de protection satisfaisante, quelle
que soit la souche vaccinale utilisée. En revanche, une pro-
tection totale ne peut être atteinte qu’après un rappel. Les
conséquences pour des essais de vaccination ultérieurs et les
orientations à prendre dans la recherche sont discutées.
Mots-clés : Bovin - Péripneumonie contagieuse bovine - Vac-
cin - Kenya.
Resumen
Wesonga H.O., Thiaucourt F. Estudios experimentales sobre
la eficiencia de las cepas de vacunas T1sr y T1/44 de Myco-
plasma mycoides subespecie mycoides (colonia pequeña)
contra un aislamiento de campo causante de la pleuroneu-
monía contagiosa bovina en Kenia. Efecto de la revacunación
La pleuroneumonía contagiosa bovina (CBPP) es una enfer-
medad importante en el ganado, causante de serias pérdidas
en la industria pecuaria en Africa. Se controla principalmente
a través de la vacunación. Sin embargo, recientes observa-
ciones de campo indican que la vacuna actualmente en uso
no logra proteger al ganado en caso de brotes, preocupando a
las autoridades veterinarias de los países afectados. Un estu-
dio de campo fue llevado a cabo, con el fin de determinar las
causas del fracaso de la vacuna. Las cepas de vacunas de
T1/44 y T1sr de Mycoplasma mycoides subespecie mycoides
(colonia pequeña) se usaron para vacunar un grupo de 40
animales por cepa. La mitad de este ganado se infectó a los
tres meses y la otra mitad a los 15 meses post vacunación,
respectivamente. La mitad del ganado utilizado en el segundo
experimento fue vacunado nuevamente un año después de la
primera vacunación. Una dosis de 107 micoplasmas por mili-
litro se usó en las vacunaciones tanto en la primera, como en
la secunda. En el primer estudio (tres meses después de la pri-
mera vacunación), la eficiencia fue de 68,2 y 59% para las
vacunas de T1sr y T1/44 respectivamente. En el segundo estu-
dio, la eficiencia fue de 80,5 y de 95,5% para las vacunas de
T1sr y T1/44 respectivamente, para el ganado vacunado dos
veces, mientras que en el ganado vacunado una sola vez y
infectado a los quince meses después de la primera vacuna-
ción, la eficiencia fue de 28,7 y 78,2% para las vacunas de
T1sr y T1/44 respectivamente. Estos resultados concuerdan
con aquellos obtenidos en estudios anteriores y además apor-
tan nueva y valiosa información. Muestran que una vacuna-
ción única, cualquiera que sea la cepa, a una dosis mínima,
no provee protección satisfactoria y que una protección total
puede obtenerse mediante una revacunación. Se discuten las
implicaciones para los estudios e investigaciones de vacuna-
ción futuros.
Palabras clave: Ganado bovino - Pleuropneumonía conta-
giosa bovina - Vacuna - Kenia.
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